A Single Centre, Double-blind, Randomised, Placebo-controlled, and Single Dose-ascending Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Single Intravenous Doses of GSK2315698 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2017
At a glance
- Drugs GSK 2315698 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 18 Jan 2017 Status changed from recruiting to completed.
- 21 Nov 2016 Status changed from not yet recruiting to recruiting.
- 08 Nov 2016 New trial record